1. Scrip

New CF Patient Subset For Vertex With Kaftrio's EU Approval

Opportunity Opens Following EU Approval Of Triple Combination

 
• By John Davis

EU approval came quicker than expected for Vertex’s new triple-combination CFTR drug, Kaftrio.   

Lungs
• Source: Shutterstock

A new subgroup of cystic fibrosis patients in the EU will be treatable with a CFTR modulator following the EU’s approval of Vertex Pharmaceuticals Incorporated.’s triple combination Kaftrio (ivacaftor/tezacaftor/elexacaftor).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.